© 2021 MJH Life Sciences and Dermatology Times and Multimedia Medical, LLC. All rights reserved.
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
April 09, 2021
ICYMI, some of this week’s featured content includes stories on the cyberwar against health care practices, the link between oxytocin and skin aging, baricitinib for alopecia areata, plus more.
April 08, 2021
Learn more about what treatments are on the rise for plaque psoriasis, the latest management advice and what trends are shaping the future of the disease.
Timber Pharmaceuticals's phase 2b trial of isotretinoin for congenital ichthyosis (CI) has reached 50% enrollment.
An array of agents for blocking visible light and lightening skin are joining the armamentarium to treat melasma. Despite this expanding number of therapeutic interventions, melasma is a chronic, therapeutically challenging disease for which there is no cure, so treatment plans should address both management of the disease and patient expectations.
Eli Lilly and Incyte announce results from its phase 3 study evaluating baricitinib 2 mg and 4 mg for the treatment of alopecia areata, making it the first Phase 3 study with top-line results in patients with the hair disorder.
In this episode, Nicole Hayre, MD, FAAD, discusses her research on the link between the "love hormone" oxytocin and younger-looking skin.
Determine whether a laser device is a good investment for a specific practice and, if so, how to choose the right piece of equipment.
April 07, 2021
AbbVie announces the submission of regulatory filings for risankizumab to the FDA and EMA seeking approval for the drug as a treatment for psoriatic arthritis.
A recent study in the Journal of Cosmetic Dermatology examines the safety and efficacy of using vitamin D intralesional injection for the treatment of keloid scars.
How hackers plan to attack your practice—and what you can do about it.
April 06, 2021
New treatments continue to expand therapy options, but a cure remains elusive.
A study found psoriasis patients treated with biologic therapy had a significant reduction in high-risk plaque in heart arteries over 1 year.
A new study in Arthritis Care & Research found depression and anxiety reduces the possibility of achieving minimal disease activity in patients with psoriatic arthritis.
April 05, 2021
This week’s edition of The Mainstream Patient features stories on sweat reduction, vitamin C serums and sensitive skin, the importance of sebum, plus more.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
April 02, 2021
ICYMI, some of this week’s featured content includes what FDA approvals to watch for in April, trending skin care, navigating the match process, plus more.
The AAD announced it will begin accepting applications soon for its 2021 Hair Loss and Alopecia Initiative in Research (HAIR) Grant Program, which focuses on helping fund research for hair disorders, especially in diverse populations.
April 01, 2021
Explore the dermatologic drugs the FDA will make a decision to approve during April 2021.
Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of April.
March 31, 2021
Biofrontera announces it is seeking FDA-approval for its new BF-RhodoLED XL lamp to be used in combination with topical aminolevulinic acid hydrochloride gel 10% for the treatment of actinic keratosis.